Norikazu Ohtake

1.3k citations

57 papers · 1.0k indexed · h-index 18

Co-authors: Kazuhito Noguchi Akira Naya Toshihiko Saeki Kenji Ohwaki Makoto Ishikawa Toshiaki Mase Yoshio Ogino Hisashi Iwaasa
Topics: Receptor Mechanisms and Signaling (21 papers)Neuropeptides and Animal Physiology (16 papers)Antibiotic Resistance in Bacteria (12 papers)
Cited by: Endocrine and Autonomic Systems Molecular Medicine Organic Chemistry
Journals: Biochemical and Biophysical Research Communications Journal of Medicinal Chemistry Antimicrobial Agents and Chemotherapy
Partner nations: Japan United States United Kingdom

In The Last Decade

Norikazu Ohtake

56 papers receiving 968 citations

Peers

Countries citing papers authored by Norikazu Ohtake

Since Specialization

Citations

This map shows the geographic impact of Norikazu Ohtake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norikazu Ohtake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norikazu Ohtake more than expected).

Fields of papers citing papers by Norikazu Ohtake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norikazu Ohtake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norikazu Ohtake. The network helps show where Norikazu Ohtake may publish in the future.

Co-authorship network of co-authors of Norikazu Ohtake

This figure shows the co-authorship network connecting the top 25 collaborators of Norikazu Ohtake. A scholar is included among the top collaborators of Norikazu Ohtake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norikazu Ohtake. Norikazu Ohtake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High-Contrast PET Imaging of Vasopressin V_1B Receptors with a Novel Radioligand, ¹¹C-TASP699 2017 ·Journal of Nuclear Medicine ·Kazumi Koga,Yuji Nagai,Masayuki Hanyu,(unknown),Shigeyuki Chaki,Norikazu Ohtake,Satoshi Ozaki,Ming‐Rong Zhang,Tetsuya Suhara,Makoto Higuchi	8
2	Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide 2017 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Yuko Araki,(unknown),(unknown),Hiroshi Kawamoto,(unknown),(unknown),Takeshi Aoki,Norikazu Ohtake	12
3	TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor 2016 ·Journal of Pharmacology and Experimental Therapeutics ·K. Koga,(unknown),(unknown),Yuji Nagai,(unknown),(unknown),Masayuki Fujinaga,Takafumi Minamimoto,Mingming Zhang,Makoto Higuchi,Norikazu Ohtake,Tetsuya Suhara,Shigeyuki Chaki	3
4	Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists 2010 ·Bioorganic & Medicinal Chemistry ·Yuji Haga,Sayaka Mizutani,Akira Naya,(unknown),Hisashi Iwaasa,Masahiko Ito,Junko Itô,Minoru Moriya,Nagaaki Sato,Norihiro Takenaga,Akane Ishihara,Shigeru Tokita,Akio Kanatani,Norikazu Ohtake	8
5	Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice 2009 ·European Journal of Pharmacology ·Masahiko Ito,Akane Ishihara,Akira Gomori,Shinichiro Egashira,Hiroko Matsushita,Satoshi Mashiko,Junko Itô,Makoto Ito,(unknown),Yuji Haga,Hisashi Iwaasa,Takao Suzuki,Norikazu Ohtake,Minoru Moriya,Nagaaki Sato,Douglas J. MacNeil,Norihiro Takenaga,Shigeru Tokita,Akio Kanatani	18
6	Discovery and structure–activity relationships of a novel class of quinazoline glucokinase activators 2009 ·Bioorganic & Medicinal Chemistry Letters ·Tomoharu Iino,Yasuhiro Sasaki,(unknown),Morihiro Mitsuya,Akio Ohno,Kenji Kamata,Hideka Hosaka,(unknown),Mayumi Futamura,(unknown),Sumika Ohyama,Kaori Sasaki,Masato Chiba,Norikazu Ohtake,Yasufumi Nagata,Jun‐ichi Eiki,T. Nishimura	33
7	Syntheses and structure–activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·Yoshio Ogino,Norikazu Ohtake,(unknown),Kenji Matsuda,Makoto Ishikawa,Minoru Moriya,(unknown),Yuko Mitobe,Junko Itô,Tetsuya Kanno,Akane Ishihara,Hisashi Iwaasa,Tomoyuki Ohe,Akio Kanatani,Takehiro Fukami	19
8	Identification of a Novel 4-Aminomethylpiperidine Class of M₃Muscarinic Receptor Antagonists and Structural Insight into Their M₃Selectivity 2006 ·Journal of Medicinal Chemistry ·(unknown),Takeshi Sagara,(unknown),Sachie Otsuki,Toshifumi Kimura,Toru Fujikawa,Kazuhito Noguchi,Norikazu Ohtake	8
9	Convenient synthesis of 2-alkylamino-6-carboxy-5,7-diarylcyclopenteno[1,2-b]pyridines via direct acylamination with imidoyl chlorides 2005 ·Tetrahedron ·(unknown),(unknown),Takehiro Fukami,(unknown),(unknown),Hiroyuki Takahashi,Toshihiro Sakamoto,T. Nishimura,Masayuki Nakamura,(unknown),Kenji Niiyama,Norikazu Ohtake,Takashi Hayama	5
10	N- Acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist 2003 ·Bioorganic & Medicinal Chemistry Letters ·Masaaki Hirose,Shinichiro Egashira,Yasuhiro Gotô,Takashi Hashihayata,Norikazu Ohtake,Hisashi Iwaasa,M. Hata,Takehiro Fukami,Akio Kanatani,Kôji Yamada	84
11	Identification of novel muscarinic M3 selective antagonists with a conformationally restricted Hyp-Pro spacer 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Toshifumi Kimura,Toru Fujikawa,Kazuhito Noguchi,Norikazu Ohtake	12
12	Structure–activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists 2003 ·Bioorganic & Medicinal Chemistry ·Akira Naya,Makoto Ishikawa,Kenji Matsuda,Kenji Ohwaki,Toshihiko Saeki,Kazuhito Noguchi,Norikazu Ohtake	56
13	Structure–Activity Relationships of 1β-Methyl-2-(5-phenylpyrrolidin-3-ylthio)carbapenems 2002 ·Bioorganic & Medicinal Chemistry ·Hiroki Sato,Hiroki Sakoh,Takashi Hashihayata,Hideaki Imamura,Norikazu Ohtake,Aya Shimizu,Yuichi Sugimoto,Shunji Sakuraba,(unknown),Koji Yamada,Terutaka Hashizume,Hajime Morishima	8
14	Identification of a Potent and Nonpeptidyl CCR3 Antagonist 2001 ·Biochemical and Biophysical Research Communications ·Toshihiko Saeki,Kenji Ohwaki,Akira Naya,Kensuke Kobayashi,Makoto Ishikawa,Norikazu Ohtake,Kazuhito Noguchi	22
15	Structure–activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems. Part 2: J-111,225, J-114,870, J-114,871 and related compounds 2000 ·Bioorganic & Medicinal Chemistry Letters ·Hideaki Imamura,Norikazu Ohtake,Aya Shimizu,Hiroki Sato,Yuichi Sugimoto,Shunji Sakuraba,(unknown),(unknown),Masato Nakano,Rie Nagano,Koji Yamada,Terutaka Hashizume,Hajime Morishima	6
16	Discovery of a muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors among 2-[(1S,3S)-3-sulfonylaminocyclopentyl]phenylacetamide derivatives 2000 ·Bioorganic & Medicinal Chemistry ·Morihiro Mitsuya,Yoshio Ogino,(unknown),(unknown),Toshifumi Kimura,(unknown),Takuro Hasegawa,Norikazu Ohtake,Kazuhito Noguchi,Toshiaki Mase	17
17	Structure–activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems. Part 1: J-111,347 and related compounds 2000 ·Bioorganic & Medicinal Chemistry Letters ·Hideaki Imamura,Norikazu Ohtake,Aya Shimizu,Hideki Jona,Hiroki Sato,Rie Nagano,(unknown),Koji Yamada,Terutaka Hashizume,Hajime Morishima	17
18	1.BETA.-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 1. Synthesis and Antibacterial Activity of B0-2502A and lts Related Compoundsf. 1997 ·The Journal of Antibiotics ·Norikazu Ohtake,Koji Yamada,(unknown),Osamu Okamoto,(unknown),Susumu Nakagawa	5
19	1,a-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and Antibacterial Activity of BO-2727 and Its Related Compounds. 1997 ·The Journal of Antibiotics ·Norikazu Ohtake,Osamu Okamoto,(unknown),Y. Kato,Katsumi Yamamoto,Yuji Haga,Hiroshi Fukatsu,Susumu Nakagawa	14
20	Resistance to a new catecholic cepbem, BO-1341, in Pseudomonas aeruginosa PAO 1992 ·Journal of Antimicrobial Chemotherapy ·(unknown),(unknown),(unknown),Norikazu Ohtake,(unknown)	5

About Norikazu Ohtake

Norikazu Ohtake is a scholar working on Molecular Medicine, Cellular and Molecular Neuroscience and Endocrine and Autonomic Systems, having authored 57 papers that have together received 1.0k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (21 papers), Neuropeptides and Animal Physiology (16 papers) and Antibiotic Resistance in Bacteria (12 papers). The work is most often cited by research in Endocrine and Autonomic Systems (115 citations), Molecular Medicine (72 citations) and Organic Chemistry (408 citations). Norikazu Ohtake has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kazuhito Noguchi, Akira Naya, Toshihiko Saeki, Kenji Ohwaki, Makoto Ishikawa, Toshiaki Mase, Yoshio Ogino, Hisashi Iwaasa, Takehiro Fukami and Kensuke Kobayashi. Their work appears in journals such as Biochemical and Biophysical Research Communications, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact